J.A. Chen, G.I. Papakostas, S.J. Youn, L. Baer, A.J. Clain, M. Fava, and D. Mischoulon Association between patient belief regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group J. Clin. Psychiatry 72 12 2011 1669 1676
P.S. Ciechanowski, W.J. Katon, J.E. Russo, and E.A. Walker The patient-provider relationship: attachment theory and adherence to treatment in diabetes Am. J. Psychiatry 158 2001 29 35
K. Demyttenaere, D. Desaiah, C. Petit, J. Croenlein, and S. Brecht Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder Prim. Care Companion J. Clin. Psychiatry 11 1 2009 8 15
K. Demyttenaere, A. Verhaeghen, N. Dantchev, L. Grassi, A.L. Montejo, D.G. Perahia, D. Quail, C. Reed, A. Tylee, and M. Bauer Caseness for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories Prim. Care Companion J. Clin. Psychiatry 11 6 2009 307 315
K. Demyttenaere, E.H. Reines, S.L. Lönn, and M. Lader Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitaloprram or serotonin-norepinephrine reuptake inhibitors: a post-hoc analysis Prim. Care Companion CNS Disord. 13 4 2011 10.4088/PCC.10m01080
Demyttenaere K.; Donneau A.F.; Albert A.; Ansseau M.; Constant E.; van Heeringen K. Physician and patient diverge in their expectations from antidepressant treatment (1). 2014, in press
M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
Hypericum Depression Trial Study Group Effect of hypericum perforatum (St John's Wort) in major depressive disorder: a randomized controlled trial JAMA 287 14 2002 1807 1814
K. Kroenke, R.L. Spitzer, and J.B. Williams The PHQ-9: validity of a brief depression severity measure J. Gen. Intern. Med. 16 2001 606 613
K. Kroenke, R.L. Spitzer, and J.B.W. Williams The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms Psychosomat. Med. 64 2002 258 266
K.M. McKay, Z.E. Imel, and B.E.J. Wampold Psychiatrist effects in the psychopharmacological treatment of depression J. Affect. Disord. 92 2-3 2006 287 290
B. Meyer, J.L. Krupnick, S.J. Simmens, P.A. Pilkonis, M.K. Egan, and S.M. Sotsky Treatment expectancies, patient alliance, and outcome: further analyses from the National Institute of Mental Health treatment of depression collaborative research program J. Consult. Clin. Psychol. 70 4 2002 1051 1055
G.I. Papakostas, and M. Fava Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD Eur. Neuropsychopharmcol. 19 2009 34 40
G.I. Papakostas, M.E. Thase, M. Fava, J.C. Nelson, and R.C. Shelton Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents Biol. Psychiatry 62 2007 1217 1227
L.J. Rane, A. Fekadu, S. Wooderson, L. Poon, K. Markopoulou, and A.J. Cleare Discrepancy between subjective and objective severity in treatment-resistant depression: prediction of treatment outcome J. Psychiatr. Res. 44 2010 1082 1087
A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, D. Warden, G. Niederehe, M.E. Thase, P.W. Lavori, B.D. Lebowitz, P.J. McGrath, J.F. Rosenbaum, H.A. Sackeim, D.J. Kupfer, J. Luther, and M. Fava Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report Am. J. Psychiatry 163 2006 1905 1917
B.R. Rutherford, M.M. Wall, A. Glas, and J.W. Stewart The role of patient expectancy in placebo and nocebo effects in antidepressant trials J. Clin. Psychiatry 75 10 2014 1040 1046
D.V. Sheehan, K. Harnett-Sheehan, and B.A. Raj The measurement of disability Int. Clin. Psychopharmacol. 11 Suppl. 3 1996 S89 S95
D.V. Sheehan, M.S. Keene, M. Eaddy, S. Krulewicz, J.E. Kraus, and D.J. Carpenter Differences in medication adherence and healthcare utilizations patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders CNS Drugs 22 11 2008 963 973
M. Sinyor, A.J. Levitt, A.H. Cheung, A. Schaffer, A. Kiss, Y. Dowlati, and K.L. Lanctôt Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses J. Clin. Psyciatry 71 3 2010 270 279
M.E. Thase, P.T. Ninan, J.J. Musgnung, and M.H. Trivedi Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study (PCC.10m00979) Prim. Care Companion CNS Disord. 13 1 2011 10.488/PCC.10m00979blu
The WHOQOL Group Development of the World Health Organization WHOQOL-BREF quality of life assessment Psychol. Med. 28 3 1998 551 558
D. Watson, L.A. Clark, and A. Tellegen Development and validation of brief measures of positive and negative affect: the PANAS scales J. Personal. Soc. Psychol. 54 6 1988 1063 1070
A.S. Zigmond, and R.P. Snaith The hospital anxiety and depression scale Acta Psychiatr. Scand. 67 1983 361 370
M. Zimmerman, J.A. Martinez, N. Attiullah, M. Friedman, C. Toba, D.A. Boerescu, and M. Rahgeb Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J. Clin. Psychiatry 73 6 2012 790 795
D.C. Zuroff, and S.J. Blatt The therapeutic relationship in the brief treatment of depression: contributions to clinical improvement and enhanced adaptive capacities J. Consult. Clin. Psychol. 74 1 2006 130 140